Indocyanine Green-guided Omental Shield Anastomosis for Cervical Esophagogastric Anastomosis in Minimally Invasive McKeown Esophagectomy

Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorDaping Hospital and the Research Institute of Surgery of the Third Military Medical University

About this trial

Brief Summary Study title: Indocyanine green (ICG)-guided omental shield anastomosis (ICG-OSA) technique for cervical esophagogastric anastomosis in esophageal cancer surgery Purpose: To evaluate whether a novel surgical technique can reduce the risk of anastomotic leakage after minimally invasive esophageal cancer surgery.

Eligible participants: Adults aged 18-80 years with histologically confirmed esophageal squamous cell carcinoma (ESCC) in the middle or lower thoracic esophagus who are scheduled for esophagectomy.

The technique: All participants will undergo the ICG-OSA procedure, which uses indocyanine green fluorescence imaging to assess gastric perfusion, creates a T-shaped esophagogastric anastomosis, and wraps the anastomosis with a pedicled omental flap.

Outcome assessments: The primary outcome is anastomotic leakage rate within 30 days after surgery. Secondary assessments include surgical site infection, anastomotic stricture, and hospitalization costs.

Study site: Daping Hospital, Army Medical Center, Chongqing, China Study duration: December 2025 to March 2027 Contact: For more information, please contact the research team at Daping hospital.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18 to 80 years, of both sexes;

Pathological diagnosis: Histologically confirmed esophageal squamous cell carcinoma (ESCC) by biopsy;

Clinical staging: Preoperative clinical stage cT1-4aN0-3M0 (according to the 8th edition AJCC staging criteria), evaluated by the thoracic surgery team as eligible for radical McKeown esophagectomy;

Performance status ECOG 0-1;

Disqualifiers

Allergy history: History of allergy to indocyanine green (ICG), iodide, or iodinated contrast agents (ICG contains iodine, and allergy may cause severe anaphylactic reactions);

Severe hepatic or renal dysfunction: Severe hepatic insufficiency (Child-Pugh Class C) or severe renal insufficiency (eGFR <30 mL/min/1.73 m²), affecting ICG metabolism and excretion;

Unfavorable tumor location: Tumor located in the cervical or upper thoracic esophagus (<25 cm from the incisors), making it difficult to ensure negative proximal resection margin;

Previous surgery history: Prior history of esophageal, gastric, or mediastinal surgery resulting in altered anatomy or severe adhesions;

Trial design

Design model

Single group

Treatments tested in this trial

  • Indocyanine green-guided omental shield anastomosis for cervical esophagogastric anastomosis

    Procedure/Surgery

    Step 1: ICG-guided gastric conduit prep: IV ICG fluorescence laparoscopy assesses gastroepiploic arcade (Koskas types) and perfusion zones (red=good, blue=poor), marks optimal anastomotic site on greater curvature, optimizes conduit tailoring. Step 2: T-Shaped Stapled Anastomosis\*\*: 1cm opening on posterior greater curvature wall at best perfusion zone, side-to-side stapling of posterior esophagus to greater curvature, closes common opening, reinforces with absorbable sutures. Step 3: Omental Shield: mobilizes pedicled omentum with good blood supply, 360° sleeve-wrap of anastomosis + 2cm area, fixes with 4-6 absorbable sutures to gastric wall above/below, ensures no tension/torsion.

Treatment groups

73 Participants
are divided into 1 treatment group
Group A: Indocyanine Green-Guided Omental Shield Anastomosis (ICG-OSA) Intervention GroupExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Anastomotic leakage rate within 30 days postoperatively

Anastomotic leakage rate assessed by clinical evaluation, computed tomography (CT) scan with oral contrast, and endoscopy according to ECCG criteria.

Time frame
Up to 30 days postoperatively (critical assessment window: postoperative day 7±1)

Secondary outcomes

1

Subclinical anastomotic leakage rate

Turbid mediastinal drainage fluid with positive bacterial culture, but requiring no intervention (i.e., no puncture drainage, stent placement, or surgery); daily recording of drainage fluid characteristics, with positive culture results confirmed by laboratory reports.

Time frame
Daily through postoperative day 30
2

Postoperative anastomotic stenosis rate

Anastomotic stricture rate diagnosed by endoscopy and dysphagia symptoms.

Time frame
6 months postoperatively
3

Anastomotic leakage-related complication rate

Complications directly related to anastomotic leakage, including pulmonary infection, empyema, mediastinal infection, and sepsis. Complications will be graded using the Clavien-Dindo classification system. Diagnosis will be confirmed by clinical symptoms (fever, leukocytosis), microbiological cultures, and imaging findings (CT scan showing fluid collections or air-fluid levels). Each complication will be documented with onset date, severity grade, and required interventions.

Time frame
Up to 30 days postoperatively
4

Health economic indicators

Total medical costs from hospital admission to discharge, including operation fees, anesthesia, medication, laboratory tests, imaging studies, hospital bed, and other related expenses. Data will be extracted from the hospital information system (HIS) at discharge and recorded in the case report form.Number of days from the date of surgery to hospital discharge, calculated as (discharge date minus surgery date + 1 day).

Time frame
From hospital admission through hospital discharge, an average of 10 days

Other outcomes

1

Technique-related adverse events

1. ICG-related reactions: Allergic reactions (rash, anaphylaxis). 2. Gastric conduit complications: Ischemia/necrosis of gastric tube, gastric emptying disorder, staple line bleeding. 3. Omental flap complications: Omental necrosis, poor wound healing at omental harvest site. 4. Anastomotic technical issues: Stapler misfire, anastomotic bleeding requiring intervention.

Time frame
From intraoperative period through 30 days postoperatively

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: